Allakos Inc. (ALLK)’s Financial Results Comparing With Mirati Therapeutics Inc. (NASDAQ:MRTX)

Allakos Inc. (NASDAQ:ALLK) and Mirati Therapeutics Inc. (NASDAQ:MRTX) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Allakos Inc. 40 0.00 N/A -1.27 0.00
Mirati Therapeutics Inc. 78 756.12 N/A -3.83 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Allakos Inc. and Mirati Therapeutics Inc.

Profitability

Table 2 has Allakos Inc. and Mirati Therapeutics Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Allakos Inc. 0.00% -46.6% -33.6%
Mirati Therapeutics Inc. 0.00% -52.1% -47.4%

Liquidity

The Current Ratio and Quick Ratio of Allakos Inc. are 20.5 and 20.5 respectively. Its competitor Mirati Therapeutics Inc.’s Current Ratio is 12.2 and its Quick Ratio is 12.2. Allakos Inc. can pay off short and long-term obligations better than Mirati Therapeutics Inc.

Analyst Ratings

Recommendations and Ratings for Allakos Inc. and Mirati Therapeutics Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Allakos Inc. 0 0 0 0.00
Mirati Therapeutics Inc. 0 1 4 2.80

Competitively Mirati Therapeutics Inc. has an average price target of $81.33, with potential downside of -17.56%.

Insider & Institutional Ownership

Allakos Inc. and Mirati Therapeutics Inc. has shares held by institutional investors as follows: 85% and 0%. Competitively, 0.4% are Mirati Therapeutics Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Allakos Inc. 2.97% 10.77% 19.79% -21.67% 0% -20.32%
Mirati Therapeutics Inc. -8.76% -2.58% -12.04% 60.52% 71.62% 49.69%

For the past year Allakos Inc. had bearish trend while Mirati Therapeutics Inc. had bullish trend.

Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in San Carlos, California.

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companyÂ’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. Its clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for glesatinib. Mirati Therapeutics, Inc. is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.